AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Probable proton-coupled zinc antiporter SLC30A4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O14863

UPID:

ZNT4_HUMAN

Alternative names:

Solute carrier family 30 member 4; Zinc transporter 4

Alternative UPACC:

O14863; Q8TC39

Background:

The Probable proton-coupled zinc antiporter SLC30A4, also known as Solute carrier family 30 member 4 or Zinc transporter 4, plays a crucial role in zinc homeostasis. It is believed to function as a proton-coupled zinc ion antiporter, facilitating the import of zinc ions from the cytoplasm potentially into the endocytic compartment. This protein is also implicated in controlling zinc deposition in milk, highlighting its significance in nutritional science.

Therapeutic significance:

Understanding the role of Probable proton-coupled zinc antiporter SLC30A4 could open doors to potential therapeutic strategies. Its involvement in zinc ion transport suggests a pivotal function in cellular zinc homeostasis, which is essential for numerous biological processes and could be targeted in various disease contexts.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.